Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...
Breyanzi is approved for relapsed or refractory marginal zone lymphoma after two prior systemic therapies, showing high response rates in clinical trials. The TRANSCEND FL-MZL Cohort trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results